A5079263297- Immunotherapy and Immune Responses
- SARS-CoV-2 and COVID-19 Research
- Cancer Immunotherapy and Biomarkers
- Mosquito-borne diseases and control
- RNA Interference and Gene Delivery
- Viral Infections and Vectors
- CAR-T cell therapy research
- Monoclonal and Polyclonal Antibodies Research
- Bacterial Infections and Vaccines
- Malaria Research and Control
- Vaccine Coverage and Hesitancy
- Lymphoma Diagnosis and Treatment
- Immune responses and vaccinations
- Virus-based gene therapy research
- Virology and Viral Diseases
- vaccines and immunoinformatics approaches
- Bladder and Urothelial Cancer Treatments
- Viral Infections and Immunology Research
University of Rhode Island
2018-2019
Providence College
2018-2019
Abstract SARS-CoV-2 has resulted in high levels of morbidity and mortality world-wide, severe complications can occur older populations. Humoral immunity induced by authorized vaccines wanes within 6 months, frequent boosts may only offer transient protection. GRT-R910 is an investigational self-amplifying mRNA (samRNA)-based vaccine delivering full-length Spike selected conserved non-Spike T cell epitopes. This study reports interim analyses for a phase I open-label dose-escalation trial...
Abstract Background Protection against COVID-19 from authorized SARS-CoV-2 vaccines diminishes after six months, so it is evident we need a second-generation vaccine that provides durable cross-variant protection through antibody responses and/or T cell to conserved epitopes. CORAL-CEPI (NCT05435027) Phase I study conducted in South Africa evaluating three self-amplifying mRNA (samRNA)-based candidates.Figure 1Vaccine Cassette Design GRT-R914 encodes full length SpikeBeta and epitopes (TCE)...
Dengue virus (DENV) and Zika (ZIKV) are mosquito-borne pathogens that have a significant impact on human health. Immune sera, mAbs, memory B cells (MBCs) isolated from patients infected with one DENV type can be cross-reactive the other three serotypes even more distantly related flaviviruses such as ZIKV. Conventional ELISPOTs effectively measure Ab-secreting but because they limited to assessment of single Ag at time, it is challenging distinguish serotype-specific MBCs in same well. We...
Prior exposure to dengue virus (DENV) has a profound impact on the outcome of infection, which varies according interval between infections. Antibodies secreted by B cells and cytokines T are thought contribute both protective immunity against DENV pathogenesis disease. We analyzed peripheral blood mononuclear (PBMC) collected from Thai children over 5-year prospective cohort study define dynamics DENV-specific memory cell responses symptomatic or subclinical To measure responses, PBMC were...
Abstract Accurate prediction of peptide presentation by HLA molecules is important for generation effective individualized cancer vaccines and immunotherapies. While algorithms class I have been successfully applied in the context such therapies, improved II are needed. EDGE-II a novel algorithm based on protein large language model that has learned allele deconvolution network trained existing new immunopeptidomics data. It delivers state-of-the-art performance immunogenicity elicited CD4+...
Abstract The immunogenicity and efficacy of RNA-based vaccine platforms has been abundantly shown through their application in prophylactic SARS-CoV2 vaccines. Contrasting to mRNA based vectors, self amplifying may offer dose-sparing superior induction T cell responses, also trigger distinct innate immune pathways, which exert adjuvanting or inhibiting effects on vaccine-induced immunity. Optimal dosing for a novel self-amplifying (SAM) heterologous prime-boost vaccination approach...
Abstract Mutations in the KRAS gene are among most common driver mutations cancer. Targeting G12C has shown some promise clinical studies, though acquired resistance pose a challenge for small molecule-based monotherapies. Vaccines targeting remain highly desirable durable tumor control and benefit to patients with solid tumors. While cytotoxic CD8 T cells critical clearance, CD4 cell activation is key component of anti-tumor response. Cancer neoepitopes homology infectious diseases antigens...
Abstract Background Neutralizing antibodies (nAbs) induced by authorized SARS-CoV-2 vaccines wane within months, requiring frequent boosters. Preliminary safety and immunogenicity of a samRNA-based vaccine candidate (GRT-R910) administered as booster following AZD1222 primary series in older (≥ 60 years) adults (Cohorts 1 & 2, CORAL-BOOST study, NCT05148962) were previously reported. Updated results GRT-R910 2-dose who received either or mRNA 3 (C3) 4 (C4)) are now Methods encodes Wuhan...
Abstract Background CORAL-CEPI (NCT05435027) is the first test of samRNA-based SARS-CoV-2 vaccines in African population, under-represented vaccine studies. Antibody transience an issue with generation vaccines. This a preliminary safety and immunogenicity report, showing durable IgG neutralizing antibody (nAb) responses induced by samRNA candidates South population.Fig. 1GRT-R914 encoding full-length Beta spike partial sequences Nucleocapsid, ORF3a, Membrane, Non-structural Proteins (NSP)...
Abstract Disclosures Ciaran Scallan, PhD, Gritstone Bio: Salaried employee of Gritstone|Gritstone Stocks/Bonds Andrew Ustianowski, MD, Gilead: Advisor/Consultant|Gilead: Board Member|Gilead: Honoraria|Gilead: Speaker fees|Pfizer: Honoraria|Pfizer: fees|Vir/GlaxoSmithKline: Advisor/Consultant|Vir/GlaxoSmithKline: Member. Background The SARS-CoV-2 pandemic continues, with new variants concern fueling periodic increases in COVID-19 cases. Authorized vaccines have provided protection against...